Compare Amgen, Inc. (AMGN) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Raymond James Financial, Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Raymond James Financial, Inc. trades at $168.12 (market cap $32.76B). The key difference: Amgen, Inc. is far larger — about 6× Raymond James Financial, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | RJF | |
|---|---|---|
Market Cap | $196.12B | $32.76B |
Sector | Health | Financials |
52-Week High | $388.16 | $176.43 |
52-Week Low | $271.18 | $140.89 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Raymond James Financial (RJF) trades at $168.12, down 0.36% today, with a bullish technical signal and strong earnings momentum after beating estimates in three consecutive quarters. Revenue growth is robust, with 2025 revenue reaching $13.84B and net income of $2.14B, though profit margins have moderated slightly. Analyst consensus is positive with a $176.83 price target, and the company maintains a solid dividend, recently declaring $0.54 per share payable in July 2026.
The outlook for RJF is favorable, supported by earnings beats and strategic investments, but risks include rising expenses and market volatility. Upside potential exists if cost management improves and revenue growth sustains, aligning with analyst targets. Key risks are competitive pressures and economic sensitivity, yet institutional sentiment remains bullish with no sell ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
